Durvalumab plus FLOT improves overall survival in resectable gastric cancer

The MATTERHORN phase 3 trial randomised 948 adults with resectable gastric or gastro-oesophageal junction adenocarcinoma to perioperative durvalumab plus FLOT chemotherapy or placebo plus FLOT. The trial reported a significant overall survival improvement with durvalumab (hazard ratio 0.78, 95% CI 0.63-0.96; p=0.021), building on previously reported event-free survival benefit. Treatment-related deaths occurred in 6 of 475 participants on durvalumab versus 2 of 469 on placebo; the authors state the regimen is a new standard treatment option for this population.

Most relevant for: Patients with resectable stage II-IVa gastric or gastro-oesophageal junction adenocarcinoma being considered for perioperative chemotherapy and surgery.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.